RETURN ON INVESTMENT OF SMOKING CESSATION BENEFIT COMPARISON IN GUANGDONG, CHINA
Author(s)
Liu D1, Zhu S2, Dong P1
1Pfizer Investment Co., Ltd., Beijing, China, 2Shenyang Pharmaceutical University, Shenyang, China
Presentation Documents
OBJECTIVES: Knowing the return-on-investment of smoking cessation (SC) is critical for policy makers to understand its economic benefit and implement effective SC intervention. The study sought to assess the return-on-investment (ROI) of smoking cessation in Guangdong, China and inform its economic benefit to policy makers. METHODS: A decision tree model about ROI of SC benefit comparison was developed and adapted, which compared the costs, benefits and outcomes of 2 SC benefit scenarios over 20-year time frame. The main difference between the 2 scenarios was whether SC medicines were covered or not. Key inputs were obtained from available public sources, including smoking population, potential medical costs and savings along with productivity improvement, participants’ expected quit rates and relapses, etc. RESULTS: If SC medicines are covered, the number of attempts and successes will increase 11 million and 1.3 million respectively in 20 years in Guangdong; the annual medical cost saving will exceed the annual cessation cost in the 6th year and it will be 7.7 times in the 20th year; the annual medial cost plus productivity saving will exceed the annual cessation cost in the 4th year and it will be 9.5 times in the 20th year; the cumulative medical cost saving will exceed the cumulative cessation cost in the 11th year and it will be 2.5 times in the 20th year; the cumulative medical cost plus productivity saving will exceed the cumulative cessation cost in the 7th year and it will be 3.4 times in the 20th year. CONCLUSIONS: Considering the attractive ROI results, it’s recommended that SC medicines should be covered in the SC intervention.
Conference/Value in Health Info
2015-05, ISPOR 2015, Philadelphia, PA, USA
Value in Health, Vol. 18, No. 3 (May 2015)
Code
PRS51
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Respiratory-Related Disorders